New therapies shaping the future of amyloidosis
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
CC122: a new IMiD in the treatment of diffuse large B-cell lymphoma
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Improving patient outcomes in acute lymphoblastic leukemia at ASH 2015